Imugene Ltd (ASX:IMU), an Australian clinical-stage immuno-oncology company, announced on Thursday that it has entered a co-development collaboration with JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a Chinese biotechnology company involved in cell-based immunotherapies.

The co-development collaboration will assess the combination of Imugene's oncolytic virus CF33-CD19 (onCARlytics) and JW's Carteyva -- a CD19-directed autologous CAR-T cell therapy -- for patients with advanced solid tumours.

The partnership includes preclinical in vitro and in vivo studies, following a phase one investigator-initiated trial to be carried out exclusively in China at premier CAR-T clinical centres.

Leslie Chong, Imugene managing director and CEO, said, "This collaboration allows us to validate our onCARlytics platform in combination with an approved autologous CAR-T product. We believe Carteyva, which is already approved in blood cancer, is an ideal choice, and this initiative enables us to generate impactful data efficiently while exploring a breakthrough treatment paradigm for solid tumours."